Medivir
Medivir AB is a clinical-stage Swedish biopharmaceutical enterprise headquartered in Huddinge, Sweden. The company focuses on the development of innovative targeted therapies for the treatment of cancer indications, anchored by its proprietary clinical pipeline featuring drug candidates addressing primary liver cancer and oncology. Principal revenue is currently earned through research grants, pharmaceutical partnerships, and licensing milestone payments as drug candidates advance through clinical trials. Medivir AB is publicly listed on Nasdaq Stockholm.
5 of the funds FundTelligence covers report a position in Medivir.
- Legal name
- Medivir Ab
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 5
Funds holding Medivir
- Cicero Hållbar Mix — Cicero Fonder · 0.34 % (full portfolio disclosed, June 2026)
- Nordea Nordic Small Cap — Nordea Funds · 0.17 % (full portfolio disclosed, July 2026)
- Nordea Nordic Small Cap Fund — Nordea Funds · 0.17 % (full portfolio disclosed, July 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.04 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.03 % (full portfolio disclosed, October 2026)